Uromigos Live 2024 RCC IO Rechallenge Part 4: What About CTLA-4-Based Salvage After IO in RCC?

At Uromigos Live 2024, a panel moderated by Tom Powles focused on IO rechallenge in renal cell carcinoma, featuring discussion on new trial data, The panel included Brian Rini, along with Tian Zhang, MD, UT Southwestern Medical Center; Toni Choueiri, MD, Dana-Farber Cancer Center; and David McDermott, MD, Beth Israel Deaconess Medical Center.
In the final part of this session, the panel discusses the nuances of re-challenging patients with PD-1 therapies in metastatic settings, focusing on renal cell carcinoma. They explore the effectiveness of immune checkpoint inhibitors like ipilimumab in salvage scenarios, particularly after disease progression following initial PD-1 therapy. The conversation highlights varying perspectives on whether to use combinations like ipilimumab and nivolumab or VEGF-TKI/IO combinations when re-challenging. They also compare treatment strategies for different cancer types, cautioning against assuming the same response across tumor types such as melanoma, bladder cancer, and kidney cancer. The panel also considers how trial data influences clinical decisions regarding late relapses and re-challenge approaches.